A detailed history of Armistice Capital, LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Armistice Capital, LLC holds 1,650,000 shares of PRTA stock, worth $25.1 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares
1,650,000
Previous 1,560,000 5.77%
Holding current value
$25.1 Million
Previous $32.2 Million 14.27%
% of portfolio
0.46%
Previous 0.42%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$16.73 - $24.79 $1.51 Million - $2.23 Million
90,000 Added 5.77%
1,650,000 $27.6 Million
Q2 2024

Aug 14, 2024

BUY
$19.54 - $26.15 $9.07 Million - $12.1 Million
464,000 Added 42.34%
1,560,000 $32.2 Million
Q1 2024

May 15, 2024

BUY
$24.75 - $40.66 $20.2 Million - $33.3 Million
818,000 Added 294.24%
1,096,000 $27.1 Million
Q4 2023

Feb 13, 2024

BUY
$32.31 - $52.32 $8.98 Million - $14.5 Million
278,000 New
278,000 $10.1 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $714M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.